Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer

June 22, 2017
Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses findings of CheckMate-032, a study of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in patients with advanced/metastatic chemotherapy-refractory gastric, esophageal, or gastroesophageal junction cancer.